The global omega 3 market was valued at USD 7.55 billion in 2025. The market is projected to grow from USD 8.1 billion in 2026 to USD 14.12 billion by 2034, exhibiting a compound annual growth rate of 7.2% during the forecast period. Contrive Datum Insights presents this information in its report titled "Omega 3 Market Size, Share & Industry Analysis, By Type (Docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), Alpha-linolenic acid (ALA)), Source (Marine Source, Fish Oil, Algal Oil, Krill Oil, Others, Plant Source, Nuts & Seeds, Vegetable Oils, Soy), Dietary supplements (Grocery Retailers, Pharmacies and Drug Stores, Internet Retailing, Others), Application (Supplements & Functional Foods, Pharmaceuticals, Infant Formula, Animal Feed & Pet Food, Others), Form (Softgel Capsules, Liquid, Powder, Gummies, Others), and Regional Forecast, 2026-2034".
Omega-3 refers to a family of polyunsaturated fatty acids, principally EPA, DHA and ALA, extracted from marine sources such as fish, krill and algae or from plant sources such as flaxseed, chia and soy, and sold as a standalone ingredient or a finished consumer product. Manufacturers of dietary supplements, functional foods, infant formula, pharmaceuticals and animal feed buy it as a refined oil, powder or encapsulated dose to fortify their own products with cardiovascular, cognitive or developmental health claims. Buyers range from ingredient formulators sourcing bulk concentrate to retail consumers purchasing finished softgels, liquids or gummies directly.
Rising cardiovascular and cognitive-health supplementation demand
Rising cardiovascular and cognitive-health supplementation demand is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 7.2% a year, the type lines exposed to it move fastest: Eicosapentaenoic acid (EPA) compounds at 8.42%, taking its share of revenue from 36.16% to 40.01% and its value from USD 2.73 billion to USD 5.65 billion.
On the upside, the study's bull case assumes prescription-grade EPA pharmaceuticals gain faster reimbursement approval across major markets and algal-oil capacity additions arrive on or ahead of schedule, letting substitution away from wild-catch fish oil proceed without a price penalty, which would take 2034 revenue to USD 16.01 billion against the USD 14.12 billion base case.
The downside is specific. Fishery yields tighten further and a delay in reimbursement or regulatory approval slows prescription-grade EPA adoption, while infant-formula fortification mandates in emerging markets are enforced more slowly than currently scheduled, and 2034 revenue lands at USD 12.34 billion. Docosahexaenoic acid (DHA) is the drag, 50.6% of the 2025 base compounding at 6.59% while the market runs at 7.2%.
Key Players Compete on Docosahexaenoic acid (DHA) Volume and Eicosapentaenoic acid (EPA) Growth
The type axis, not the regional one, is what divides the field. Docosahexaenoic acid (DHA) is the volume position, 50.6% of 2025 revenue at USD 3.82 billion, holding 48.02% through 2034, and it is defended by scale. Eicosapentaenoic acid (EPA) is the growth position at 8.42%, and it is open. Strength in one does not carry into the other.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Docosahexaenoic acid (DHA) | 50.6% · USD 3.82 billion | — |
| Source | Fish Oil | 40% · USD 3.02 billion | Algal Oil 10.99% |
| Dietary supplements | Grocery Retailers | 38.01% · USD 2.87 billion | Internet Retailing 11.16% |
| Application | Supplements & Functional Foods | 51.98% · USD 3.93 billion | Pharmaceuticals 10.68% |
| Form | Softgel Capsules | 54.97% · USD 4.15 billion | Gummies 15.04% |
- North America was the largest region in 2025, holding 34% of global revenue at USD 2.57 billion and reaching USD 4.38 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 26% in 2025 to 32% in 2034, with revenue growing from USD 1.96 billion to USD 4.52 billion.
- Middle East and Africa stays the smallest contributor across the period: 6% of revenue in 2025 and 5% in 2034.
- No type line grows faster than Eicosapentaenoic acid (EPA), at a projected 8.42%.
- The United States is the largest single country market at USD 2.06 billion in 2025, 27.3% of global revenue.
Coverage runs to five axes, by type, and by source, dietary supplements, application and form, with a revenue figure and a growth rate for every line in every year from 2020 to 2034, and bear, base and bull cases on the headline total at USD 12.34 billion and USD 16.01 billion by 2034. All five regions are broken out to country level, alongside the competitive landscape and the methodology behind each estimate. The study is delivered as a PDF, and a free sample can be requested.